Article

Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation

Received:
Accepted:
Published online:

Abstract

The ability to engineer custom cell-contact-sensing output devices into human nonimmune cells would be useful for extending the applicability of cell-based cancer therapies and for avoiding risks associated with engineered immune cells. Here we have developed a new class of synthetic T-cell receptor–like signal-transduction device that functions efficiently in human nonimmune cells and triggers release of output molecules specifically upon sensing contact with a target cell. This device employs an interleukin signaling cascade, whose OFF/ON switching is controlled by biophysical segregation of a transmembrane signal-inhibitory protein from the sensor cell–target cell interface. We further show that designer nonimmune cells equipped with this device driving expression of a membrane-penetrator/prodrug-activating enzyme construct could specifically kill target cells in the presence of the prodrug, indicating its potential usefulness for target-cell-specific, cell-based enzyme-prodrug cancer therapy. Our study also contributes to the advancement of synthetic biology by extending available design principles to transmit extracellular information to cells.

  • Subscribe to Nature Chemical Biology for full access:

    $59

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Accessions

Primary accessions

References

  1. 1.

    , & CAR T cell therapy: a game changer in cancer treatment. J. Immunol. Res. 2016, 5474602 (2016).

  2. 2.

    , & Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).

  3. 3.

    , & Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9, 704–716 (2009).

  4. 4.

    , , & CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy 7, 487–497 (2015).

  5. 5.

    , & Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells. Curr. Opin. Chem. Biol. 28, 29–38 (2015).

  6. 6.

    , & Toward a world of theranostic medication: Programming biological sentinel systems for therapeutic intervention. Adv. Drug Deliv. Rev. 105, 66–76 (2016).

  7. 7.

    et al. New strategies for the treatment of solid tumors with CAR-T cells. Int. J. Biol. Sci. 12, 718–729 (2016).

  8. 8.

    , , & Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolytics 3, 16011 (2016).

  9. 9.

    & Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy 18, 1393–1409 (2016).

  10. 10.

    et al. Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc. Natl. Acad. Sci. USA 111, 5896–5901 (2014).

  11. 11.

    , , , & Antitumor activity of a mesenchymal stem cell line stably secreting a tumor-targeted TNF-related apoptosis-inducing ligand fusion protein. Front. Immunol. 8, 536 (2017).

  12. 12.

    et al. Probe-based confocal laser endomicroscopy for imaging TRAIL-expressing mesenchymal stem cells to monitor colon xenograft tumors in vivo. PLoS One 11, e0162700 (2016).

  13. 13.

    et al. Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases. J. Exp. Clin. Cancer Res. 34, 33 (2015).

  14. 14.

    et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl. Med. 2, 983–992 (2013).

  15. 15.

    et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci. Transl. Med. 5, 184ra59 (2013).

  16. 16.

    , , & Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors. Biochimie 105, 4–11 (2014).

  17. 17.

    , & Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. J. Control. Release 200, 179–187 (2015).

  18. 18.

    et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780–791 (2016).

  19. 19.

    et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016).

  20. 20.

    et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419–432 e16 (2016).

  21. 21.

    et al. Initiation of T cell signaling by CD45 segregation at 'close contacts'. Nat. Immunol. 17, 574–582 (2016).

  22. 22.

    & Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 487, 64–69 (2012).

  23. 23.

    et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349–354 (2001).

  24. 24.

    , , & Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis. Sci. Transl. Med. 7, 318ra201 (2015).

  25. 25.

    et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709–717 (2005).

  26. 26.

    , , , & Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013, 434010 (2013).

  27. 27.

    Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489–511 (2015).

  28. 28.

    , & EpCAM: structure and function in health and disease. Biochim. Biophys. Acta 1828, 1989–2001 (2013).

  29. 29.

    , , & Properties of cell penetrating peptides (CPPs). IUBMB Life 58, 7–13 (2006).

  30. 30.

    & Cellular internalization of green fluorescent protein fused with herpes simplex virus protein VP22 via a lipid raft-mediated endocytic pathway independent of caveolae and Rho family GTPases but dependent on dynamin and Arf6. J. Biol. Chem. 282, 27503–27517 (2007).

  31. 31.

    & Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88, 223–233 (1997).

  32. 32.

    & Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 6, 149–151 (1999).

  33. 33.

    et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60, 3813–3822 (2000).

  34. 34.

    et al. Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination. Mol. Ther. 17, 1373–1380 (2009).

  35. 35.

    et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120, 3953–3968 (2010).

  36. 36.

    & Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900–911 (2003).

  37. 37.

    & IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. 155, 1079–1090 (1995).

  38. 38.

    & Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 278, 3226–3245 (2011).

  39. 39.

    , & Engineering death receptor ligands for cancer therapy. Cancer Lett. 332, 163–174 (2013).

  40. 40.

    , & Synthetic biology-the synthesis of biology. Angew. Chem. Int. Ed. Engl. 56, 6396–6419 (2017).

  41. 41.

    & Synthetic biology—toward therapeutic solutions. J. Mol. Biol. 428, 945–962 (2016).

  42. 42.

    et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat. Biotechnol. 20, 592–596 (2002).

Download references

Acknowledgements

We thank P. Saxena for critical comments on the manuscript, R. Vale, J. James, B. Lindner, J. Schaefer, S. Rosenberg, A. Plückthun, L. Schukur, H. Chassin, and Addgene construct suppliers (see Supplementary Information) for providing plasmids, T. Lopes and V. Jaggin for help with FACS analysis, and E. Montani, A. Ponti, and T. Horn for help with microscopy. This work was supported by the European Research Council (ERC) advanced grant (ProNet, no. 321381) and in part by the National Centre of Competence in Research (NCCR) for Molecular Systems Engineering. R.K. was supported by a postdoctoral fellowship by the Human Frontier Science Program (HFSP; LT000094/2014-L).

Author information

Affiliations

  1. ETH Zurich, Department of Biosystems Science and Engineering, Basel, Switzerland.

    • Ryosuke Kojima
    • , Leo Scheller
    •  & Martin Fussenegger
  2. Faculty of Life Science, University of Basel, Basel, Switzerland.

    • Martin Fussenegger

Authors

  1. Search for Ryosuke Kojima in:

  2. Search for Leo Scheller in:

  3. Search for Martin Fussenegger in:

Contributions

R.K. and M.F. designed the project, analyzed the results, and wrote the manuscript. R.K. performed experimental work. L.S. contributed to project design and plasmid generation and edited the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Martin Fussenegger.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Results, Supplementary Tables 1–2 and Supplementary Figures 1–5

  2. 2.

    Life Sciences Reporting Summary